CTIX Potential Catalysts and Past Milestones Q2 2016

CTIX Potential Catalysts and Past Milestones

Q2 2016 Potential Catalysts

- P top-line data (Phase 2)
- B-OM interim data (Phase 2)
- K top-line data (Phase 1)
- Start of B-ABSSSI (Phase 3)
- Start of B-UP (Phase 2, proof of concept)
- Start of K-ovarian (Phase 2)
- Fast track designation for B-ABSSSI
- ASM Microbe presentations (June 19-20)

Past Milestones

- QIDP designation for B-ABSSSI
- Fast track designation for B-OM
- Orphan drug designation for K-ovarian cancer
- Orphan drug designation for K-pancreatic cancer
- Orphan drug designation for K-retinoblastoma
- Rare pediatric disease designation for K-retinoblastoma
- B-ABSSSI positive Phase 2b top-line & bottom line data
- Completion of cohort 11 (750 mg/m2)
- K positive primary outcome (Phase 1)
- P positive primary outcome (Phase 1)
- Stable formulation of B at room temperature
- MTA extension on testing B in implanted devices

Clinical Trials

1. P (Phase 1, completed): https://clinicaltrials.gov/ct2/show/NCT024944...amp;rank=1
2. P (Phase 2, not recruiting): https://clinicaltrials.gov/ct2/show/NCT021012...amp;rank=2
3. B-OM (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT023243...amp;rank=3
4. B-ABSSSI (Phase 2, completed): https://clinicaltrials.gov/ct2/show/NCT020523...amp;rank=4
5. K (Phase 1, completed): https://clinicaltrials.gov/ct2/show/NCT016640...amp;rank=5

Abbreviations

K – Kevetrin
B – Brilacidin
P – Prurisol
ABSSSI – acute bacterial skin and skin structure infections
OM – oral mucositis
UP – ulcerative proctitis
QIDP – qualified infectious disease product